These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

457 related articles for article (PubMed ID: 34012921)

  • 1. Escape From Treatment; the Different Faces of Leukemic Stem Cells and Therapy Resistance in Acute Myeloid Leukemia.
    van Gils N; Denkers F; Smit L
    Front Oncol; 2021; 11():659253. PubMed ID: 34012921
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting histone methylation to reprogram the transcriptional state that drives survival of drug-tolerant myeloid leukemia persisters.
    van Gils N; Verhagen HJMP; Broux M; Martiáñez T; Denkers F; Vermue E; Rutten A; Csikós T; Demeyer S; Çil M; Al M; Cools J; Janssen JJWM; Ossenkoppele GJ; Menezes RX; Smit L
    iScience; 2022 Sep; 25(9):105013. PubMed ID: 36097617
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Specific Depletion of Leukemic Stem Cells: Can MicroRNAs Make the Difference?
    Martiáñez Canales T; de Leeuw DC; Vermue E; Ossenkoppele GJ; Smit L
    Cancers (Basel); 2017 Jun; 9(7):. PubMed ID: 28665351
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Convergent epigenetic evolution drives relapse in acute myeloid leukemia.
    Nuno K; Azizi A; Koehnke T; Lareau C; Ediriwickrema A; Corces MR; Satpathy AT; Majeti R
    Elife; 2024 Apr; 13():. PubMed ID: 38647535
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Acute Myeloid Leukemia Stem Cells in Minimal/Measurable Residual Disease Detection.
    Srinivasan Rajsri K; Roy N; Chakraborty S
    Cancers (Basel); 2023 May; 15(10):. PubMed ID: 37345204
    [TBL] [Abstract][Full Text] [Related]  

  • 6. MRD in Venetoclax-Based Treatment for AML: Does it Really Matter?
    Bernardi M; Ferrara F; Carrabba MG; Mastaglio S; Lorentino F; Vago L; Ciceri F
    Front Oncol; 2022; 12():890871. PubMed ID: 35924144
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Characteristics of leukemic stem cells in acute leukemia and potential targeted therapies for their specific eradication.
    Hansen Q; Bachas C; Smit L; Cloos J
    Cancer Drug Resist; 2022; 5(2):344-367. PubMed ID: 35800375
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Leukemic Target with a Thousand Faces: The Mitochondria.
    Maffeo B; Panuzzo C; Moraca A; Cilloni D
    Int J Mol Sci; 2023 Aug; 24(17):. PubMed ID: 37685874
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Leukemic stem cells and therapy resistance in acute myeloid leukemia.
    Stelmach P; Trumpp A
    Haematologica; 2023 Feb; 108(2):353-366. PubMed ID: 36722405
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Molecular patterns of response and treatment failure after frontline venetoclax combinations in older patients with AML.
    DiNardo CD; Tiong IS; Quaglieri A; MacRaild S; Loghavi S; Brown FC; Thijssen R; Pomilio G; Ivey A; Salmon JM; Glytsou C; Fleming SA; Zhang Q; Ma H; Patel KP; Kornblau SM; Xu Z; Chua CC; Chen X; Blombery P; Flensburg C; Cummings N; Aifantis I; Kantarjian H; Huang DCS; Roberts AW; Majewski IJ; Konopleva M; Wei AH
    Blood; 2020 Mar; 135(11):791-803. PubMed ID: 31932844
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Jiyuan oridonin A induces differentiation of acute myeloid leukemia cells including leukemic stem-like cells.
    Li F; Gao C; Li X; Wang J; Zhao Y; Ke Y; Liu Y; Liu HM; Hu Z; Wei L; Chen ZS
    Front Pharmacol; 2022; 13():1001552. PubMed ID: 36133825
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Measurable Residual Disease in High-Risk Acute Myeloid Leukemia.
    Cluzeau T; Lemoli RM; McCloskey J; Cooper T
    Cancers (Basel); 2022 Mar; 14(5):. PubMed ID: 35267586
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The pan-Bcl2 Inhibitor AT101 Activates the Intrinsic Apoptotic Pathway and Causes DNA Damage in Acute Myeloid Leukemia Stem-Like Cells.
    Zhang L; Zhou Y; Chen K; Shi P; Li Y; Deng M; Jiang Z; Wang X; Li P; Xu B
    Target Oncol; 2017 Oct; 12(5):677-687. PubMed ID: 28710745
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Drug Resistance Mechanisms of Acute Myeloid Leukemia Stem Cells.
    Niu J; Peng D; Liu L
    Front Oncol; 2022; 12():896426. PubMed ID: 35865470
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Transplant characteristics: minimal residual disease and impaired megakaryocytic colony growth as sensitive parameters for predicting relapse in acute myeloid leukemia.
    Reichle A; Rothe G; Krause S; Zaiss M; Ullrich H; Schmitz G; Andreesen R
    Leukemia; 1999 Aug; 13(8):1227-34. PubMed ID: 10450751
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evolving Therapies in Acute Myeloid Leukemia: Progress at Last?
    DeAngelo DJ; Stein EM; Ravandi F
    Am Soc Clin Oncol Educ Book; 2016; 35():e302-12. PubMed ID: 27249736
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antibody-Targeted Cyclodextrin-Based Nanoparticles for siRNA Delivery in the Treatment of Acute Myeloid Leukemia: Physicochemical Characteristics, in Vitro Mechanistic Studies, and ex Vivo Patient Derived Therapeutic Efficacy.
    Guo J; Russell EG; Darcy R; Cotter TG; McKenna SL; Cahill MR; O'Driscoll CM
    Mol Pharm; 2017 Mar; 14(3):940-952. PubMed ID: 28146632
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunophenotyping investigation of minimal residual disease is a useful approach for predicting relapse in acute myeloid leukemia patients.
    San Miguel JF; Martínez A; Macedo A; Vidriales MB; López-Berges C; González M; Caballero D; García-Marcos MA; Ramos F; Fernández-Calvo J; Calmuntia MJ; Diaz-Mediavilla J; Orfao A
    Blood; 1997 Sep; 90(6):2465-70. PubMed ID: 9310499
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The genesis and evolution of acute myeloid leukemia stem cells in the microenvironment: From biology to therapeutic targeting.
    Chen Y; Li J; Xu L; Găman MA; Zou Z
    Cell Death Discov; 2022 Sep; 8(1):397. PubMed ID: 36163119
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia.
    Cloos J; Harris JR; Janssen JJWM; Kelder A; Huang F; Sijm G; Vonk M; Snel AN; Scheick JR; Scholten WJ; Carbaat-Ham J; Veldhuizen D; Hanekamp D; Oussoren-Brockhoff YJM; Kaspers GJL; Schuurhuis GJ; Sasser AK; Ossenkoppele G
    J Vis Exp; 2018 Mar; (133):. PubMed ID: 29553571
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.